Novavax (NASDAQ:NVAX) Trading Down 7.3% – What’s Next?

Novavax, Inc. (NASDAQ:NVAX)’s share price was down 7.3% on Thursday . The company traded as low as $10.36 and last traded at $10.2830. Approximately 930,816 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 4,942,366 shares. The stock had previously closed at $11.09.

Novavax News Roundup

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax rallied after reports that FDA advisers will consider updating the 2026-27 COVID-19 vaccines to target the latest XFG subvariant, potentially improving demand for vaccine makers including Novavax. Why Novavax (NVAX) Stock Is Trading Up Today
• Positive Sentiment: Options trading turned unusually bullish, with investors buying 21,279 Novavax call contracts, about 50% above typical volume, indicating increased speculation on further stock gains.
• Positive Sentiment: Zacks Research raised multiple earnings estimates for Novavax, including FY2026, FY2027, FY2028, and several interim quarters, signaling improving expectations for the company’s future profitability.
• Neutral Sentiment: Short-interest data showed no meaningful shares outstanding in the latest report, so it does not currently provide a clear near-term trading signal.

Wall Street Analyst Weigh In

A number of analysts have weighed in on NVAX shares. Wall Street Zen cut Novavax from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. HC Wainwright raised their price target on Novavax from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Weiss Ratings cut Novavax from a “hold (c-)” rating to a “sell (d)” rating in a research note on Thursday, May 7th. TD Cowen raised their price objective on Novavax from $8.00 to $9.00 and gave the stock a “hold” rating in a report on Wednesday, May 6th. Finally, B. Riley Financial reaffirmed a “buy” rating on shares of Novavax in a report on Thursday, April 9th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $12.13.

Novavax Stock Down 6.9%

The stock has a fifty day moving average of $8.85 and a 200-day moving average of $8.32. The stock has a market cap of $1.70 billion, a PE ratio of -17.73 and a beta of 2.37.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.19. Novavax had a negative return on equity of 14.82% and a negative net margin of 14.73%.The firm had revenue of $118.90 million for the quarter, compared to analyst estimates of $79.81 million. During the same quarter last year, the company posted $2.93 earnings per share. The business’s revenue was down 79.0% on a year-over-year basis. Equities research analysts forecast that Novavax, Inc. will post -0.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novavax

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Novavax by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 15,470,365 shares of the biopharmaceutical company’s stock worth $103,961,000 after buying an additional 275,802 shares during the last quarter. Shah Capital Management grew its holdings in shares of Novavax by 2.0% during the first quarter. Shah Capital Management now owns 14,845,097 shares of the biopharmaceutical company’s stock worth $120,839,000 after buying an additional 286,317 shares during the last quarter. State Street Corp grew its holdings in shares of Novavax by 32.3% during the fourth quarter. State Street Corp now owns 9,523,646 shares of the biopharmaceutical company’s stock worth $63,999,000 after buying an additional 2,326,927 shares during the last quarter. UBS Group AG grew its holdings in shares of Novavax by 40.3% during the fourth quarter. UBS Group AG now owns 4,894,284 shares of the biopharmaceutical company’s stock worth $32,890,000 after buying an additional 1,405,981 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Novavax by 0.5% in the 3rd quarter. Bank of America Corp DE now owns 3,101,074 shares of the biopharmaceutical company’s stock valued at $26,886,000 after purchasing an additional 15,685 shares in the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.